文献速递肝病消化道肿瘤与早癌

SERPINA12通过过度激活AKT/β-catenin信号促进肝细胞癌干细胞的致瘤能力

SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling.
PubMed 文献 · Hepatology · 2023-01-13

研究比较了胎儿及再生肝脏来源的上皮特异性「正常」CD133+细胞与致癌基因驱动及炎症相关肝细胞癌来源的CD133+细胞转录组,发现SERPINA12在肝细胞癌CD133+细胞中优先过表达。SERPINA12通过结合GRP78过度激活AKT/GSK3β/β-catenin信号形成正反馈环路,促进自我更新、治疗抵抗和转移。静脉给予rAAV8-shSERPINA12可使免疫健全肝细胞癌小鼠模型的肿瘤细胞对索拉非尼增敏并抑制癌症干细胞亚群。

要点

  • SERPINA12在肝细胞癌CD133+细胞中优先过表达,与生存、肿瘤分期、肝硬化和干性特征相关。
  • SERPINA12通过结合GRP78过度激活AKT/GSK3β/β-catenin信号形成正反馈环路。
  • 静脉给予rAAV8-shSERPINA12使肝细胞癌小鼠模型肿瘤细胞对索拉非尼增敏并抑制癌症干细胞亚群。

核心结论

  • SERPINA12在上皮性肝细胞癌CD133+细胞中优先过表达,通过驱动AKT/β-catenin正反馈环路促进肝细胞癌发生和进展。

研究设计与样本

  • 研究比较胎儿和再生肝脏来源的上皮特异性「正常」CD133+细胞与致癌基因驱动及炎症相关肝细胞癌来源的CD133+细胞的转录组谱。
  • 在免疫健全肝细胞癌小鼠模型中静脉给予rAAV8-shSERPINA12。

主要发现

  • SERPINA12在肝细胞癌CD133+细胞中优先过表达,而在胎儿和再生肝脏CD133+细胞中未过表达。
  • SERPINA12在肝细胞癌中的上调与侵袭性临床和干性特征紧密相关,包括生存、肿瘤分期、肝硬化和干性特征。
  • SERPINA12通过结合GRP78过度激活AKT/GSK3β/β-catenin信号级联,形成正反馈环路。
  • 静脉给予rAAV8-shSERPINA12使肝细胞癌小鼠模型肿瘤细胞对索拉非尼增敏并抑制癌症干细胞亚群。

关键数值与推荐

  • SERPINA12在肝细胞癌中的富集由β-catenin效应因子TCF7L2结合启动子驱动SERPINA12转录活性介导。
  • 内源性SERPINA12促进自我更新、治疗抵抗和转移能力。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: HCC is an aggressive disease with poor clinical outcome. Understanding the mechanisms that drive cancer stemness, which we now know is the root cause of therapy failure and tumor recurrence, is fundamental for designing improved therapeutic strategies. This study aims to identify molecular players specific to CD133 + HCC to better design drugs that can precisely interfere with cancer stem cells but not normal stem cell function. APPROACH AND RESULTS: Transcriptome profiling comparison of epithelial-specific "normal" CD133 + cells isolated from fetal and regenerating liver against "HCC" CD133 + cells isolated from proto-oncogene-driven and inflammation-associated HCC revealed preferential overexpression of SERPINA12 in HCC but not fetal and regenerating liver CD133 + cells. SERPINA12 upregulation in HCC is tightly associated with aggressive clinical and stemness features, including survival, tumor stage, cirrhosis, and stemness signatures. Enrichment of SERPINA12 in HCC is mediated by promoter binding of the well-recognized β-catenin effector TCF7L2 to drive SERPINA12 transcriptional activity. Functional characterization identified a unique and novel role of endogenous SERPINA12 in promoting self-renewal, therapy resistance, and metastatic abilities. Mechanistically, SERPINA12 functioned through binding to GRP78, resulting in a hyperactivated AKT/GSK3β/β-catenin signaling cascade, forming a positive feed-forward loop. Intravenous administration of rAAV8-shSERPINA12 sensitized HCC cells to sorafenib and impeded the cancer stem cell subset in an immunocompetent HCC mouse model. CONCLUSIONS: Collectively, our findings revealed that SERPINA12 is preferentially overexpressed in epithelial HCC CD133 + cells and is a key contributor to HCC initiation and progression by driving an AKT/β-catenin feed-forward loop.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yu H, Zhou L, Loong JHC, et al. SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling. Hepatology. 2023. PMID: 36630996. doi:10.1097/HEP.0000000000000269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。